Share Market Newspaper

(Albany, US) September 17, 2026 – DelveInsight’s “Dystrophic Epidermolysis Bullosa Pipeline Insights 2026” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Dystrophic Epidermolysis Bullosa Pipeline landscape. It covers the Dystrophic Epidermolysis Bullosa Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dystrophic Epidermolysis Bullosa pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Dystrophic Epidermolysis Bullosa research @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-pipeline-insight

Key Takeaways from the Dystrophic Epidermolysis Bullosa Pipeline Report

• In September 2026 – Abeona Therapeutics announced the activation of University of Florida Health as a new Qualified Treatment Center for ZEVASKYN (prademagene zamikeracel), expanding access to its gene-corrected cell therapy for wounds associated with recessive Dystrophic Epidermolysis Bullosa.
• On August 12, 2026- Xinnate AB initiated a study will include a Screening Period, a Treatment Period (Days 1 to 56, with study visits conducted every 2 weeks, including the baseline [Day 1], Day 14, Day 28, Day 42, and Day 56 visits) and a Safety Follow-up conducted via a telephone/video call at approximately 14 days after the last dose of the IMP. Patients will undergo efficacy, safety, tolerability, and PK assessments at scheduled visits. For evaluation of the primary efficacy endpoint, a trained clinician will take the images of the index wounds at all scheduled visits from baseline through Day 56 (Visit 6) using 3D digital photography and software for wound measurement.
• DelveInsight’s Dystrophic Epidermolysis Bullosa pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Dystrophic Epidermolysis Bullosa treatment.
• The leading Dystrophic Epidermolysis Bullosa Companies include Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL GmbH & Co. KG, Anterogen Co., Ltd., Abeona Therapeutics, Inc., InMed Pharmaceuticals, BridgeBio Inc., Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals and others.
• Promising Dystrophic Epidermolysis Bullosa Therapies such as KB803, AGLE-102, EB-101, TCP-25 gel, PTR-01, and others.

Download for updates and be a part of the revolution in cancer care @ Dystrophic Epidermolysis Bullosa Clinical Trials Assessment

The Dystrophic Epidermolysis Bullosa Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Dystrophic Epidermolysis Bullosa Pipeline Report also highlights the unmet needs with respect to the Dystrophic Epidermolysis Bullosa.

Dystrophic Epidermolysis Bullosa Overview

Dystrophic Epidermolysis Bullosa (DEB) is a rare inherited skin disorder characterized by extreme skin fragility, resulting in blistering, erosions, and wounds following minimal friction or trauma. The condition is primarily caused by mutations in the COL7A1 gene, which encodes type VII collagen, an essential protein that helps anchor the epidermis to the underlying dermis. DEB results from abnormalities in type VII collagen and the anchoring fibrils that connect the skin layers. Depending on the genetic variant and its inheritance pattern, DEB may be classified into recessive dystrophic epidermolysis bullosa (RDEB) and dominant dystrophic epidermolysis bullosa (DDEB). Patients with severe forms may experience widespread blistering, chronic wounds, scarring, and progressive complications.

Dystrophic Epidermolysis Bullosa Emerging Drugs Profile

• PTR-01: Phoenix Tissue Repair

Phoenix Tissue Repair is advancing an investigational therapy known as PTR-01, a systemic recombinant collagen type VII (rC7) for the treatment of Recessive Dystrophic Epidermolysis Bullosa. rC7 is a potentially disease-modifying drug that is delivered intravenously to patients, replacing defective collagen type VII with healthy collagen at the sites where it is needed both internally and externally. Phoenix Tissue Repair acquired worldwide rights to PTR-01 from Shire Plc in 2017 and has initiated its first clinical trial. Preclinical studies of PTR-01 have shown that it selectively anchors in the skin and other tissues affected by an absence of collagen type VII. In four animal models of the disease, intravenous injections of PTR-01 promoted healing of DEB wounds. These experiments have shown improvements in tissue structure, disease presentation and survival, indicating a restoration of natural skin architecture.

• FCX-007: Castle Creek Biosciences

D-Fi, also known as FCX-007, (dabocemagene autoficel), is being developed as an ex vivo, autologous cell-based gene therapy to address the deficiency of functional COL7 in patients with dystrophic epidermolysis bullosa (DEB). D-Fi has been clinically studied in a Phase 1/2 clinical study (NCT02810951), which assessed 6 patients with RDEB. In this study, 80% (8/10) of treated chronic wounds demonstrated complete wound healing 12 weeks after the first injection of D-Fi, while none of the untreated wounds were healed. D-Fi was well tolerated post-administration with few reports of temporary redness or discoloration at the injection site. D-Fi is currently in Phase 3 clinical development for the localized treatment of chronic wounds in individuals with RDEB.

Learn more about Dystrophic Epidermolysis Bullosa drug opportunities in our groundbreaking research and development projects @ Dystrophic Epidermolysis Bullosa Unmet Needs

The Dystrophic Epidermolysis Bullosa Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Dystrophic Epidermolysis Bullosa with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dystrophic Epidermolysis Bullosa Treatment.
• Dystrophic Epidermolysis Bullosa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dystrophic Epidermolysis Bullosa Drugs under development are based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dystrophic Epidermolysis Bullosa market.

Dystrophic Epidermolysis Bullosa Companies

Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL GmbH & Co. KG, Anterogen Co., Ltd., Abeona Therapeutics, Inc., InMed Pharmaceuticals, BridgeBio Inc., Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals and others

The Dystrophic Epidermolysis Bullosa Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Dystrophic Epidermolysis Bullosa Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Stay informed about how we’re transforming the future of oncology @ Dystrophic Epidermolysis Bullosa Market Drivers and Barriers, and Future Perspectives

Scope of the Dystrophic Epidermolysis Bullosa Pipeline Report

• Coverage- Global
• Dystrophic Epidermolysis Bullosa Companies- Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL GmbH & Co. KG, Anterogen Co., Ltd., Abeona Therapeutics, Inc., InMed Pharmaceuticals, BridgeBio Inc., Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals and others.
• Dystrophic Epidermolysis Bullosa Therapies– KB803, AGLE-102, EB-101, TCP-25 gel, PTR-01, and others.
• Dystrophic Epidermolysis Bullosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Dystrophic Epidermolysis Bullosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of the Dystrophic Epidermolysis Bullosa Pipeline on our website, @ Dystrophic Epidermolysis Bullosa Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Dystrophic Epidermolysis Bullosa: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. FCX-007: Castle Creek Biosciences
8. Comparative Analysis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. PTR-01: Phoenix Tissue Repair
12. Early Stage Products (Phase I)
13. Comparative Analysis
14. PTW-002: Phoenicis Therapeutics
15. Inactive Products
16. Dystrophic Epidermolysis Bullosa Key Companies
17. Dystrophic Epidermolysis Bullosa Key Products
18. Dystrophic Epidermolysis Bullosa Unmet Needs
19. Dystrophic Epidermolysis Bullosa Market Drivers and Barriers
20. Dystrophic Epidermolysis Bullosa Future Perspectives and Conclusion
21. Dystrophic Epidermolysis Bullosa Analyst Views
22. Dystrophic Epidermolysis Bullosa Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/dystrophic-epidermolysis-bullosa-pipeline-insight